RA Capital Management 13F holdings, Q4 2016
Holdings as of December 31, 2016 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 27 US equity positions worth $705.8m in its Q4 2016 13F filing. The largest position was WVE at 26.3% of the reported book, followed by ASND and AVEXIS INC. Against the Q3 2016 filing, it opened 6 new positions, added to 4 and reduced 10 among the top 27 holdings.
What did RA Capital Management own in Q4 2016? Top 27 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2016 |
|---|---|---|---|---|---|---|---|
| 1 | WVE WAVE LIFE SCIENCES LTD | Healthcare | 26.3% | $185.4m | 7,088,651 | 0% | held |
| 2 | ASND ASCENDIS PHARMA A S | Healthcare | 15.5% | $109.5m | 5,409,990 | 47% | added |
| 3 | AVEXIS INC | 12.8% | $90.2m | 1,890,796 | 9% | added | |
| 4 | ACHILLION PHARMACEUTICALS INC | 8.0% | $56.3m | 13,633,220 | 13% | added | |
| 5 | AQUINOX PHARMACEUTICALS INC | 5.1% | $36.2m | 2,191,977 | 0% | held | |
| 6 | ZOGENIX INC | 4.2% | $29.8m | 2,451,237 | -8% | reduced | |
| 7 | ARDX ARDELYX INC | Healthcare | 3.9% | $27.5m | 1,935,305 | -41% | reduced |
| 8 | RA PHARMACEUTICALS INC | 2.9% | $20.5m | 1,351,808 | – | new | |
| 9 | FOAMIX PHARMACEUTICALS LTD | 2.9% | $20.2m | 1,820,138 | 0% | held | |
| 10 | BCRX BIOCRYST PHARMACEUTICALS | Healthcare | 2.7% | $18.9m | 2,989,795 | 0% | held |
| 11 | MYOVANT SCIENCES LTD | 2.6% | $18.7m | 1,500,000 | – | new | |
| 12 | PTGX PROTAGONIST THERAPEUTICS INC | Healthcare | 2.1% | $14.6m | 692,563 | -8% | reduced |
| 13 | AIMT AIMMUNE THERAPEUTICS INC | 2.0% | $13.9m | 677,663 | -48% | reduced | |
| 14 | AUDENTES THERAPEUTICS INC | 1.4% | $9.7m | 532,426 | -25% | reduced | |
| 15 | ONC BEIGENE LTD | Healthcare | 1.0% | $7.3m | 240,000 | 41% | added |
| 16 | DICERNA PHARMACEUTICALS INC | 1.0% | $7.0m | 2,428,571 | 0% | held | |
| 17 | ABEO ABEONA THERAPEUTICS INC | 0.8% | $5.5m | 1,142,857 | – | new | |
| 18 | STRONGBRIDGE BIOPHARMA PLC | 0.8% | $5.5m | 2,279,099 | -9% | reduced | |
| 19 | TGTX TG THERAPEUTICS INC | Healthcare | 0.7% | $4.7m | 1,004,314 | -78% | reduced |
| 20 | TENX TENAX THERAPEUTICS INC | 0.7% | $4.7m | 2,389,700 | 0% | held | |
| 21 | 4XC1 KALVISTA PHARMACEUTICALS INC | 0.6% | $4.2m | 591,070 | – | new | |
| 22 | EIGER BIOPHARMACEUTICALS INC | 0.6% | $4.1m | 354,200 | 0% | held | |
| 23 | DIMENSION THERAPEUTICS INC | 0.6% | $4.0m | 928,199 | -40% | reduced | |
| 24 | IDERA PHARMACEUTICALS INC | 0.5% | $3.4m | 2,250,000 | – | new | |
| 25 | MEDICINES CO | 0.4% | $2.7m | 79,899 | – | new | |
| 26 | AKTX AKARI THERAPEUTICS PLC | 0.1% | $714.0k | 101,439 | -11% | reduced | |
| 27 | ARCA BIOPHARMA INC | 0.1% | $662.0k | 232,245 | -55% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.